The prefrontal cortex, which governs decision-making and emotional regulation
these are more likely to be seen in patients who are at a higher dose of a GLP-1 medication or who are transitioning between doses.7 There are many other potential reactions including fatigue, headaches, rashes, alopecia, anxiety, dizziness, and rejection at the injection site.7 In pediatric patients, cholelithiasis, cholecystitis, hypotension, rash, and urticaria were more likely to be seen.7 A loss of muscle mass is another concern for individuals utilizing GLP-1 medications
The product is supplied as a ready-to-use sterile solution (600 mg/ml in 10 ml vial)
Efpeglenatide, says Hanmi Pharmaceutical, is the first GLP-1 treatment for obesity and metabolic diseases developed independently in South Korea
Simply put, this is the exact same drug used to treat two different conditions, diabetes and obesity
Nat Rev Dis Primers 6 , 64 (2020)